Oncology rapid test Seralite®FLC

for hematologyserumlateral flow

Seralite® – FLC* utilises highly specific, anti-K and anti-λ monoclonal antibodies (mAbs) which are conjugated to gold particles and incorporated into a simple to use lateral flow device. The serum is added to the sample application buffer provided with the kit and then added to the sample port. The sample flows through the conjugate pad containing the gold nanoparticles coupled to mAbs. Sample, and the mAb gold conjugate flow through a membrane containing two test lines, one pre-coated with purified Κ FLC and the other with purified λ FLC. A third line made up of immobilised biotin acts as a control line. Inhibition of mAb-gold binding to the test lines indicates the presence of FLC in the sample. Schematic view of free light chain test, Seralite- FLCClick to enlarge After ~10 minutes the sample is analysed on a CE marked and FDA registered lateral flow assay reader (ADxLR5®) which reads the results of the device, quantifies the kappa and lambda FLC and calculates the ratio of Κ/λ FLC. Seralite® – FLC* is a rapid lateral flow test for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum. The format of this rapid test enables a free light chain service to be offered in all clinical laboratories. This enables the provision of FLC results in ~10 minutes rather than days or weeks. With this simple to use, compact, rapid test, clinicians are able to monitor patients in “real time” supporting faster decision making.